# Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

> **NCT04504851** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 154 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Rosuvastatin 10mg
- **DRUG:** Rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol

## Key facts

- **NCT ID:** NCT04504851
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-12
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2020-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504851, "Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04504851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*